← Back to Home

Wainua Heart Phase 3 Trial Misses Endpoint, Reshuffling the ATTR-CM Competitive Landscape

AstraZeneca and Ionis had hoped to move an RNA drug that has already gained a foothold in a rare neuropathy into the larger heart market; the late-stage trial setback forces the ATTR-CM treatment path, from “protein lowering” to “combination therapy,” back under scrutiny.

By SURL BioNews

Whether a drug can cross disease boundaries is often one of the most compelling stories in biotech. Wainua already has a commercial base in transthyretin amyloidosis with polyneuropathy, but when the same TTR protein-lowering strategy was advanced into a cardiomyopathy population, the clinical reality delivered a clearly colder answer.

AstraZeneca and Ionis said Wainua’s Phase 3 trial in transthyretin amyloid cardiomyopathy (ATTR-CM) failed to reach statistical significance on its primary endpoint. According to Investor's Business Daily, the antisense oligonucleotide therapy did not show enough additional benefit on top of standard treatment to clear the bar.

The Guardian’s real-time market report also noted that the late-stage trial did not meet its primary goal of reducing cardiovascular death and recurrent cardiovascular events; AstraZeneca therefore became one of the heaviest-falling constituents in the U.K.’s FTSE 100 index that day. The company said it will further analyze the full data and plans to present the results at the European Society of Cardiology annual meeting in August.

ATTR-CM is a disease in which TTR protein misfolds and deposits in the heart, gradually causing the heart to thicken and fail. Existing treatment approaches broadly fall into two categories: one stabilizes TTR protein to prevent it from breaking down and forming deposits; the other seeks to reduce TTR protein production. Wainua belongs to the latter group and had been expected to prove that further lowering the protein could still bring clinical benefit in patients already using TTR stabilizers.

The key to this setback is not only that a single drug has lost one indication. The ATTR-CM market has drawn competition from multiple companies in recent years, including Pfizer, BridgeBio, and Alnylam, and treatment options are moving from an early single-axis approach toward more complex patient stratification and combination strategies. If a large trial cannot prove added benefit, physicians, payers, and developers will all look more cautiously at whether “mechanistic complementarity” can truly translate into lower risk of death or hospitalization.

However, publicly available information remains limited. The companies have not yet released full data, subgroup analyses, or safety details, and it is also unclear whether different baseline treatments, disease severity, and genotypes affect interpretation of the results. Therefore, this failure should be viewed as a major blow to the evidence for clinical benefit, rather than a final verdict on all TTR-lowering strategies.

**Background Context**

Wainua’s setback reminds the market that expansion for rare disease drugs cannot proceed solely by pushing the same molecular mechanism forward. Although neuropathy and cardiomyopathy both belong to TTR amyloidosis diseases, their clinical endpoints, pace of disease progression, background treatment, and trial designs are all different; in heart disease, proving that a new drug helps patients live longer and be hospitalized less often usually carries a higher bar than improving biomarkers. The full data to be released in August will determine whether this setback was a problem of population, design, and combination therapy, or whether Wainua’s room for development in ATTR-CM has already been substantially compressed.

References

  1. Investor's Business Daily
  2. The Guardian